Ma Ning, Ge Chun-lin, Luan Feng-ming, Hu Chao-jun, Li Yong-zhe, Liu Young-feng
Department of General Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Zhonghua Wai Ke Za Zhi. 2008 Jun 15;46(12):932-5.
To detect the serum specific proteins in pancreatic cancer patients and establish diagnostic model by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) technique.
Twenty-nine serum samples from patients of pancreatic cancer were collected before surgery and an additional 57 serum samples from age and sex matched individuals without cancer were used as controls, SELDI-TOF-MS technique and WCX magnetic beads were used to detect the protein fingerprint expression of all the serum samples and the resulting profiles between pancreatic cancer patients and controls were analyzed with biomarker wizard system, established the model using biomarker patterns system software. A double-blind test was used to determine the sensitivity and specificity of the classification model.
A panel of four biomarkers (relative molecular weight are 5705, 4935, 5318 and 3243 Da) were selected to set up a decision trees as the classification model for screening pancreatic cancer effectively. The result yielded a sensitivity of 100%, specificity of 97.4%. The double-blind test challenged the model with a sensitivity of 88.9% and a specificity of 89.5%.
SELDI-TOF-MS offers a unique platform for the proteomic detection of serum in pancreatic cancer patients. It also offers a noninvasive method to further study the proteomic changes in the development and progression of pancreatic cancer.
通过表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术检测胰腺癌患者血清特异性蛋白并建立诊断模型。
收集29例胰腺癌患者术前血清样本,另选取57例年龄、性别匹配的非癌症个体血清样本作为对照,采用SELDI-TOF-MS技术及WCX磁珠检测所有血清样本的蛋白指纹图谱表达,利用生物标志物向导系统分析胰腺癌患者与对照组的图谱,采用生物标志物模式系统软件建立模型。采用双盲试验确定分类模型的敏感性和特异性。
选择一组四个生物标志物(相对分子质量分别为5705、4935、5318和3243 Da)建立决策树作为有效筛查胰腺癌的分类模型。结果显示敏感性为100%,特异性为97.4%。双盲试验对该模型进行检验,敏感性为88.9%,特异性为89.5%。
SELDI-TOF-MS为胰腺癌患者血清蛋白质组学检测提供了一个独特的平台。它还提供了一种非侵入性方法,以进一步研究胰腺癌发生发展过程中的蛋白质组学变化。